Loading…
The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients
Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despit...
Saved in:
Published in: | BMC cancer 2021-03, Vol.21 (1), p.333-333, Article 333 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3 |
container_end_page | 333 |
container_issue | 1 |
container_start_page | 333 |
container_title | BMC cancer |
container_volume | 21 |
creator | Colombié, Mathilde Jézéquel, Pascal Rubeaux, Mathieu Frenel, Jean-Sébastien Bigot, Frédéric Seegers, Valérie Campone, Mario |
description | Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner.
The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation.
Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution.
ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered. |
doi_str_mv | 10.1186/s12885-021-08060-8 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a8460bd3abbf4701b7f1fdd98a7d5b53</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A657274795</galeid><doaj_id>oai_doaj_org_article_a8460bd3abbf4701b7f1fdd98a7d5b53</doaj_id><sourcerecordid>A657274795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</originalsourceid><addsrcrecordid>eNptk99rFDEQxxdRbK3-Az5IQBAFtyabzS8fhHKc9qCg1PY5ZLOzt1t2N9skW-w_4N9t7q7WXpE8ZDL5zDeZZCbLXhN8TIjknwIppGQ5LkiOJeY4l0-yQ1IKkhclFk8f2AfZixCuMCZCYvk8O6BUSMUpO8x-X7SAlj9Wi8vzJQpxrm8_I4OmrncRTd6FCWzsbgBZ1zofdwRyDWohgndrGMHNAZmxRoMJYUPWJhrUjRHW3sTOjclGA0QTYlpaVHlIJrJmtODRlHwwxvAye9aYPsCru_kou_y6vFic5mffv60WJ2e55ZzFnNZ1w7AshCxoiS0WpTKk4YpAQVVjCXCaclRWMQApuAVSlCVRDS-FIFxU9Chb7XRrZ6705LvB-FvtTKe3DufX2vh0zR60kSXHVU1NVTWlwKQSDWnqWkkjalYxmrS-7LSmuRqgtikPb_o90f2dsWv12t1oiQkhTCWBjzuB9lHY6cmZ7sYAftCYFkSykt2QhL-_O8-76xlC1EMXLPS92X6CLhgWgmJVlAl9-wi9crMf08smKlUFp0rJf9TapHy7sXHpmnYjqk84E4UohWKJOv4PlUYNQ2fdCE2X_HsBH_YCEhPhV1ybOQS9-nm-z757wLZg-tgG18-bwgn7YLEDbSrK4KG5fzCC9aYb9K4bdOoGve0GvUnwzcMfug_5W_70D_NjAwo</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2514763998</pqid></control><display><type>article</type><title>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Colombié, Mathilde ; Jézéquel, Pascal ; Rubeaux, Mathieu ; Frenel, Jean-Sébastien ; Bigot, Frédéric ; Seegers, Valérie ; Campone, Mario</creator><creatorcontrib>Colombié, Mathilde ; Jézéquel, Pascal ; Rubeaux, Mathieu ; Frenel, Jean-Sébastien ; Bigot, Frédéric ; Seegers, Valérie ; Campone, Mario</creatorcontrib><description>Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner.
The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation.
Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution.
ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-021-08060-8</identifier><identifier>PMID: 33789635</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Algorithms ; Breast cancer ; Breast Neoplasms - epidemiology ; Cancer therapies ; Care and treatment ; Cohort ; Cohort analysis ; Cohort Studies ; Collection ; Complications and side effects ; Decision making ; Epidemiology ; Estrogens ; Evaluation ; Female ; Heterogeneous ; Humans ; Hypotheses ; Life Sciences ; Medical prognosis ; Metastases ; Metastasis ; Metastatic breast cancer ; Microbiota ; Mortality ; Multi-omics data ; Neoplasm Metastasis ; Patients ; Pilot Projects ; Practice guidelines (Medicine) ; Prediction ; Prospective Studies ; Quality of life ; Quality of Life - psychology ; Study Protocol ; Womens health</subject><ispartof>BMC cancer, 2021-03, Vol.21 (1), p.333-333, Article 333</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</citedby><cites>FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</cites><orcidid>0000-0001-9187-1394 ; 0000-0002-5273-0561 ; 0000-0002-5196-5908</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011159/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2514763998?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33789635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-03218545$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Colombié, Mathilde</creatorcontrib><creatorcontrib>Jézéquel, Pascal</creatorcontrib><creatorcontrib>Rubeaux, Mathieu</creatorcontrib><creatorcontrib>Frenel, Jean-Sébastien</creatorcontrib><creatorcontrib>Bigot, Frédéric</creatorcontrib><creatorcontrib>Seegers, Valérie</creatorcontrib><creatorcontrib>Campone, Mario</creatorcontrib><title>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner.
The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation.
Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution.
ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered.</description><subject>Algorithms</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cohort</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Collection</subject><subject>Complications and side effects</subject><subject>Decision making</subject><subject>Epidemiology</subject><subject>Estrogens</subject><subject>Evaluation</subject><subject>Female</subject><subject>Heterogeneous</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Life Sciences</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Metastatic breast cancer</subject><subject>Microbiota</subject><subject>Mortality</subject><subject>Multi-omics data</subject><subject>Neoplasm Metastasis</subject><subject>Patients</subject><subject>Pilot Projects</subject><subject>Practice guidelines (Medicine)</subject><subject>Prediction</subject><subject>Prospective Studies</subject><subject>Quality of life</subject><subject>Quality of Life - psychology</subject><subject>Study Protocol</subject><subject>Womens health</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptk99rFDEQxxdRbK3-Az5IQBAFtyabzS8fhHKc9qCg1PY5ZLOzt1t2N9skW-w_4N9t7q7WXpE8ZDL5zDeZZCbLXhN8TIjknwIppGQ5LkiOJeY4l0-yQ1IKkhclFk8f2AfZixCuMCZCYvk8O6BUSMUpO8x-X7SAlj9Wi8vzJQpxrm8_I4OmrncRTd6FCWzsbgBZ1zofdwRyDWohgndrGMHNAZmxRoMJYUPWJhrUjRHW3sTOjclGA0QTYlpaVHlIJrJmtODRlHwwxvAye9aYPsCru_kou_y6vFic5mffv60WJ2e55ZzFnNZ1w7AshCxoiS0WpTKk4YpAQVVjCXCaclRWMQApuAVSlCVRDS-FIFxU9Chb7XRrZ6705LvB-FvtTKe3DufX2vh0zR60kSXHVU1NVTWlwKQSDWnqWkkjalYxmrS-7LSmuRqgtikPb_o90f2dsWv12t1oiQkhTCWBjzuB9lHY6cmZ7sYAftCYFkSykt2QhL-_O8-76xlC1EMXLPS92X6CLhgWgmJVlAl9-wi9crMf08smKlUFp0rJf9TapHy7sXHpmnYjqk84E4UohWKJOv4PlUYNQ2fdCE2X_HsBH_YCEhPhV1ybOQS9-nm-z757wLZg-tgG18-bwgn7YLEDbSrK4KG5fzCC9aYb9K4bdOoGve0GvUnwzcMfug_5W_70D_NjAwo</recordid><startdate>20210331</startdate><enddate>20210331</enddate><creator>Colombié, Mathilde</creator><creator>Jézéquel, Pascal</creator><creator>Rubeaux, Mathieu</creator><creator>Frenel, Jean-Sébastien</creator><creator>Bigot, Frédéric</creator><creator>Seegers, Valérie</creator><creator>Campone, Mario</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9187-1394</orcidid><orcidid>https://orcid.org/0000-0002-5273-0561</orcidid><orcidid>https://orcid.org/0000-0002-5196-5908</orcidid></search><sort><creationdate>20210331</creationdate><title>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</title><author>Colombié, Mathilde ; Jézéquel, Pascal ; Rubeaux, Mathieu ; Frenel, Jean-Sébastien ; Bigot, Frédéric ; Seegers, Valérie ; Campone, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Algorithms</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cohort</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Collection</topic><topic>Complications and side effects</topic><topic>Decision making</topic><topic>Epidemiology</topic><topic>Estrogens</topic><topic>Evaluation</topic><topic>Female</topic><topic>Heterogeneous</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Life Sciences</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Metastatic breast cancer</topic><topic>Microbiota</topic><topic>Mortality</topic><topic>Multi-omics data</topic><topic>Neoplasm Metastasis</topic><topic>Patients</topic><topic>Pilot Projects</topic><topic>Practice guidelines (Medicine)</topic><topic>Prediction</topic><topic>Prospective Studies</topic><topic>Quality of life</topic><topic>Quality of Life - psychology</topic><topic>Study Protocol</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colombié, Mathilde</creatorcontrib><creatorcontrib>Jézéquel, Pascal</creatorcontrib><creatorcontrib>Rubeaux, Mathieu</creatorcontrib><creatorcontrib>Frenel, Jean-Sébastien</creatorcontrib><creatorcontrib>Bigot, Frédéric</creatorcontrib><creatorcontrib>Seegers, Valérie</creatorcontrib><creatorcontrib>Campone, Mario</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colombié, Mathilde</au><au>Jézéquel, Pascal</au><au>Rubeaux, Mathieu</au><au>Frenel, Jean-Sébastien</au><au>Bigot, Frédéric</au><au>Seegers, Valérie</au><au>Campone, Mario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2021-03-31</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>333</spage><epage>333</epage><pages>333-333</pages><artnum>333</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner.
The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation.
Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution.
ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33789635</pmid><doi>10.1186/s12885-021-08060-8</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9187-1394</orcidid><orcidid>https://orcid.org/0000-0002-5273-0561</orcidid><orcidid>https://orcid.org/0000-0002-5196-5908</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2407 |
ispartof | BMC cancer, 2021-03, Vol.21 (1), p.333-333, Article 333 |
issn | 1471-2407 1471-2407 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_a8460bd3abbf4701b7f1fdd98a7d5b53 |
source | Publicly Available Content Database; PubMed Central |
subjects | Algorithms Breast cancer Breast Neoplasms - epidemiology Cancer therapies Care and treatment Cohort Cohort analysis Cohort Studies Collection Complications and side effects Decision making Epidemiology Estrogens Evaluation Female Heterogeneous Humans Hypotheses Life Sciences Medical prognosis Metastases Metastasis Metastatic breast cancer Microbiota Mortality Multi-omics data Neoplasm Metastasis Patients Pilot Projects Practice guidelines (Medicine) Prediction Prospective Studies Quality of life Quality of Life - psychology Study Protocol Womens health |
title | The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A12%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20EPICURE%20study:%20a%20pilot%20prospective%20cohort%20study%20of%20heterogeneous%20and%20massive%20data%20integration%20in%20metastatic%20breast%20cancer%20patients&rft.jtitle=BMC%20cancer&rft.au=Colombi%C3%A9,%20Mathilde&rft.date=2021-03-31&rft.volume=21&rft.issue=1&rft.spage=333&rft.epage=333&rft.pages=333-333&rft.artnum=333&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-021-08060-8&rft_dat=%3Cgale_doaj_%3EA657274795%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2514763998&rft_id=info:pmid/33789635&rft_galeid=A657274795&rfr_iscdi=true |